Corporate ActionJun 9, 2026, 10:51 PM
Tango Therapeutics Prices $600M Public Offering of Stock & Warrants
AI Summary
Tango Therapeutics, a clinical-stage biotechnology company, announced the pricing of an underwritten public offering expected to generate approximately $600 million in gross proceeds. The offering includes 18,166,667 shares of common stock priced at $30.00 per share and pre-funded warrants for up to 1,833,395 shares at $29.999 each. The company has also granted the underwriters a 30-day option to purchase an additional 3,000,009 shares of common stock.
Key Highlights
- Tango Therapeutics priced an underwritten public offering to raise approximately $600 million in gross proceeds.
- The offering includes 18,166,667 shares of common stock priced at $30.00 per share.
- It also includes pre-funded warrants to purchase up to 1,833,395 shares at $29.999 per warrant.
- Underwriters have a 30-day option to purchase an additional 3,000,009 shares of common stock.
- The offering is expected to close on or about June 11, 2026, subject to customary conditions.
Price Impact
More from TNGX